Rani Therapeutics Holdings (RANI) Stock Statistics & Valuation Metrics

Rani Therapeutics Holdings has a market cap or net worth of $76.22M. The enterprise value is $101.03M.

Market Cap

$76.22M

Enterprise Value

$101.03M

Rani Therapeutics Holdings has 115,424,960 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding

115,424,960

Owned by Insiders

22.00%

Owned by Institutions

9.03%

Rani Therapeutics Holdings’s return on equity (ROE) is -0.90 and return on invested capital (ROIC) is -80.59%.

Return on Equity (ROE)

-0.90

Return on Assets (ROA)

-0.51

Return on Invested Capital (ROIC)

-80.59%

Return on Capital Employed (ROCE)

-0.83

Revenue Per Employee

23.33K

Profits Per Employee

-423.90K

Employee Count

70

Asset Turnover

0.03

Inventory Turnover

0.00

The current PE Ratio of Rani Therapeutics Holdings is -3.04. Rani Therapeutics Holdings’s PEG ratio is -0.02.

PE Ratio

-3.04

PS Ratio

7.69

PB Ratio

3.36

Price to FCF

-1.62

Price to Operating Cash Flow

-4.97

PEG Ratio

-0.02

In the last 12 months, Rani Therapeutics Holdings had revenue of 1.63M and earned -29.67M in profits. Earnings per share was -0.45.

Revenue

1.63M

Gross Profit

733.00K

Operating Income

-38.31M

Pretax Income

-40.95M

Net Income

-29.67M

EBITDA

-37.16M

Earnings Per Share (EPS)

-0.45

In the last 12 months, operating cash flow was -22.99M and capital expenditures -230,000, giving a free cash flow of -23.22M billion.

Operating Cash Flow

-22.99M

Free Cash Flow

-23.22M

Free Cash Flow per Share

-0.12

Rani Therapeutics Holdings pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share

―

Dividend Yield

―

Payout Ratio

N/A

Free Cash Flow Yield

-54.40%

Earnings Yield

-28.13%

Beta

2.28

52-Week Price Change

-75.95%

50-Day Moving Average

0.74

200-Day Moving Average

0.90

Relative Strength Index (RSI)

34.30

Average Volume (3m)

585.12K

Rani Therapeutics Holdings upcoming earnings date is Mar 31, 2027, TBA (Not Confirmed).

Last Earnings Date

Nov 05, 2026

Next Earnings Date

Mar 31, 2027

Ex-Dividend Date

―

Rani Therapeutics Holdings as a current ratio of 4.21, with Debt / Equity ratio of 13.08%

Current Ratio

4.21

Quick Ratio

4.21

Debt to Market Cap

0.03

Net Debt to EBITDA

0.38

Interest Coverage Ratio

-13.25

In the past 12 months, Rani Therapeutics Holdings has paid 0 in taxes.

Income Tax

0

Effective Tax Rate

0.00

Rani Therapeutics Holdings EV to EBITDA ratio is -1.13, with an EV/FCF ratio of -1.77.

EV to Sales

7.40

EV to EBITDA

-1.13

EV to Free Cash Flow

-1.77

EV to Operating Cash Flow

-1.78

Rani Therapeutics Holdings has $45.29M in cash and marketable securities with $3.15M in debt, giving a net cash position of $42.14M billion.

Cash & Marketable Securities

$45.29M

Total Debt

$3.15M

Net Cash

$42.14M

Net Cash Per Share

$0.37

Tangible Book Value Per Share

$0.21

Gross margin is 96.70%, with operating margin of -716.12%, and net profit margin of -665.53%.

Gross Margin

96.70%

Operating Margin

-716.12%

Pretax Margin

-681.55%

Net Profit Margin

-665.53%

EBITDA Margin

-701.37%

EBIT Margin

-522.49%

The average price target for Rani Therapeutics Holdings is $6.75, which is 11.43% higher than the current price. The consensus rating is Strong Buy

Price Target

$6.75

Price Target Upside

1136.26% Upside

Analyst Consensus

Strong Buy

Analyst Count

4

Revenue Growth Forecast

306.42%

EPS Growth Forecast

70.84%

Smart Score

3

AI Score

43